Extrapolation beyond the end of trials to estimate long term survival and cost effectiveness

被引：28

作者：

Latimer, Nicholas R. ^{[1
]}

Adler, Amanda I. ^{[2
]}

机构：

[1] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England

[2] Univ Oxford, Diabetes Trials Unit, Oxford, England

来源：

BMJ MEDICINE | 2022年 / 1卷 / 01期

关键词：

economics; health policy; statistics;

D O I：

10.1136/bmjmed-2021-000094

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

This paper explains the importance of extrapolating beyond the end of trials to estimate the long term benefits associated with new treatments, why this is done, and the limitations of various approaches.

引用

页数：4

共 11 条

[1] Estimating and modelling cure in population-based cancer studies within the framework of flexible parametric survival models [J].

Andersson, Therese M. L. ;

Dickman, Paul W. ;

Eloranta, Sandra ;

Lambert, Paul C. .

BMC MEDICAL RESEARCH METHODOLOGY, 2011, 11

[2]

[Anonymous], 2017, Guidelines for the economic evaluation of health technologies: Canada, V4

[3] A Review of Survival Analysis Methods Used in NICE Technology Appraisals of Cancer Treatments: Consistency, Limitations, and Areas for Improvement [J].

Bell Gorrod, Helen ;

Kearns, Ben ;

Stevens, John ;

Thokala, Praveen ;

Labeit, Alexander ;

Latimer, Nicholas ;

Tyas, David ;

Sowdani, Ahmed .

MEDICAL DECISION MAKING, 2019, 39 (08) :899-909

[4] Extrapolating Survival from Randomized Trials Using External Data: A Review of Methods [J].

Jackson, Christopher ;

Stevens, John ;

Ren, Shijie ;

Latimer, Nick ;

Bojke, Laura ;

Manca, Andrea ;

Sharples, Linda .

MEDICAL DECISION MAKING, 2017, 37 (04) :377-390

[5] Comparing current and emerging practice models for the extrapolation of survival data: a simulation study and case-study [J].

Kearns, Benjamin ;

Stevenson, Matt D. ;

Triantafyllopoulos, Kostas ;

Manca, Andrea .

BMC MEDICAL RESEARCH METHODOLOGY, 2021, 21 (01)

[6]

Latimer N., 2011, Wailoo A, ed

[7]

National Institute for Health and Care Excellence, 2021, Pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal cancer. lead team presentation

[8]

National Institute for Health and Care Excellence, 2018, Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people aged up to 25 years

[9]

National Institute for Health and Clinical Excellence, 2013, GUID METH TECHN APPR

[10] Flexible parametric proportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects [J].

Royston, P ;

Parmar, MKB .

STATISTICS IN MEDICINE, 2002, 21 (15) :2175-2197

← 1 2 →